Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

REPL
Replimune Group, Inc.
stock NASDAQ

At Close
Jun 10, 2026 3:59:55 PM EDT
8.46USD-8.442%(-0.78)3,373,780
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 10, 2026 8:51:30 AM EDT
9.04USD-2.165%(-0.20)1,819
After-hours
Jun 10, 2026 4:55:30 PM EDT
8.51USD+0.591%(+0.05)232,088
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
04:01PM EST  Replimune Announces the Departure of Dr. Otello Stampacchia from   GlobeNewswire Inc
Jan 10, 2022
07:00AM EST  CERPASSclinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter   GlobeNewswire Inc
Jan 4, 2022
08:00AM EST  Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET.   GlobeNewswire Inc
Dec 2, 2021
08:00AM EST  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Companys Board of Directors effective December 1, 2021.   GlobeNewswire Inc
Nov 19, 2021
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
06:42AM EST  Piper Sandler Initiates Coverage On Replimune Group with Overweight Rating, Announces Price Target of $52   Benzinga
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo (nivolumab)   GlobeNewswire Inc
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 4, 2021
08:23AM EDT  Replimune Group Q2 EPS $(0.56) Down From $(0.46) YoY   Benzinga
08:00AM EDT  RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022   GlobeNewswire Inc
Nov 1, 2021
08:00AM EDT  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:   GlobeNewswire Inc
Oct 1, 2021
08:23AM EDT  Replimune Announces Presentations At 2021 Society For Immunotherapy Of Cancer's 36th Annual Meeting Nov. 12-14   Benzinga
08:01AM EDT  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting being held November 10-14, 2021.   GlobeNewswire Inc
Aug 23, 2021
07:54AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:15AM EDT  SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $49   Benzinga
Aug 6, 2021
08:03AM EDT  Replimune Group Q1 EPS $(0.53) Down From $(0.44) YoY   Benzinga
08:00AM EDT  Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022   GlobeNewswire Inc
Aug 2, 2021
08:00AM EDT  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:   GlobeNewswire Inc
Jul 7, 2021
08:00AM EDT  Replimune to Present at the William Blair Biotech Focus Conference   GlobeNewswire Inc
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
07:08AM EDT  Replimune Provides Data Update From RP1 And RP2 Programs; Co. Also Announces Plans To Expand Development Of RP2/3 Beyond Phase 1   Benzinga
07:00AM EDT  High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs   GlobeNewswire Inc
May 20, 2021
08:16AM EDT  Replimune Group Reports FY21 EPS $(1.75) Down From $(1.54) YoY   Benzinga
08:00AM EDT  Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma   GlobeNewswire Inc
May 10, 2021
08:00AM EDT  Replimune Appoints Tanya Lewis as Chief Development Operations Officer   GlobeNewswire Inc
May 5, 2021
07:24AM EDT  Replimune Amends Clinical Trial Protocol Of Phase 2 CERPASS Trial To Include Complete Response Rate As A Primary Endpoint In Additional To Overall Response Rate; Also Plans to Reduce Target Enrollment From 240 To 180   Benzinga
07:00AM EDT  Replimune Provides a Regulatory Update for its Registration-   GlobeNewswire Inc
Apr 28, 2021
08:00AM EDT  Replimune to Host Virtual Investor Event on June 3, 2021   GlobeNewswire Inc
Apr 21, 2021
08:00AM EDT  Replimune Appoints Genentech Global Oncology Franchise Head Sushil   GlobeNewswire Inc
Apr 12, 2021
04:01PM EDT  Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting   Benzinga
04:01PM EDT  Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2   GlobeNewswire Inc
Mar 11, 2021
04:01PM EST  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.   GlobeNewswire Inc
Mar 4, 2021
08:00AM EST  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences.   GlobeNewswire Inc
Feb 18, 2021
08:00AM EST  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on Wednesday, February 24, 2021 at 8:40 AM ET.   GlobeNewswire Inc
Feb 5, 2021
09:28AM EST  HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $60   Benzinga
Feb 4, 2021
01:27PM EST  SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $56   Benzinga
08:03AM EST  Replimune Group Q3 EPS $(0.44) Up From $(0.46) YoY   Benzinga
08:00AM EST  RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies   GlobeNewswire Inc
Jan 11, 2021
07:15AM EST  Replimune Expects Current Cash Position to Fund Operations into 2024   Benzinga
07:00AM EST  RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies   GlobeNewswire Inc
Jan 6, 2021
08:00AM EST  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET.   GlobeNewswire Inc
Jan 5, 2021
08:25AM EST  Replimune Doses First Patient In Phase 1 Clinical Trial Of RP3   RTTNews
08:03AM EST  Replimune Announces First Patient Doses With RP3 In Phase 1 Clinical Trial In Patients With Advanced Solid Tumors   Benzinga
08:00AM EST  Replimune Announces First Patient Dosed with RP3 in a Phase 1   GlobeNewswire Inc
Nov 20, 2020
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
Nov 17, 2020
09:29AM EST  BTIG Initiates Coverage On Replimune Group with Buy Rating, Announces Price Target of $60   Benzinga
Nov 12, 2020
08:00AM EST  Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.   GlobeNewswire Inc
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
08:16AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
Nov 9, 2020
08:22AM EST  Replimune Announces Poster Presentations At The SITC 2020 Annual Meeting And A Presentation At The SITC 2020 Annual Meeting Virtual Press Conference   Benzinga
08:00AM EST  Replimune Announces Poster Presentations at the SITC 2020 Annual   GlobeNewswire Inc
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
07:29AM EST  BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $57   Benzinga
Nov 5, 2020
09:13AM EST  Replimune Filing Offering Shows Co. May Offer And Sell $62.5M Of Common Stock From Time To Time   Benzinga
08:06AM EST  Replimune Group Q2 EPS $(0.46) Down From $(0.35) YoY   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
Oct 22, 2020
10:29AM EDT  Stocks Trading Near 52-Week Highs Just After Open On Thursday, Oct. 22, 2020: MXL, LOACR, PRPH, QELLU, PBI, LOACW, ACAMW, LPL, HBM, ACAM, CSX, ALACW, ERIC, SNA, AMTX, BCOV, EVK, ALGN, TC, PAG, CRSR, WHR, SQBG, STNE, IMMU, REPL, BOTZ, ATSG, SFIX, SID   Benzinga
01:09AM EDT  Replimune Announces Pricing of Upsized Public Offering   GlobeNewswire Inc
Oct 21, 2020
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
Oct 20, 2020
04:05PM EDT  Replimmune Announces Proposed Public Offering Of $125M In Shares Of Its Common Stock   Benzinga
04:02PM EDT  Replimune Announces Proposed Public Offering   GlobeNewswire Inc
04:01PM EDT  Replimune Releases Updated Corporate Presentation   GlobeNewswire Inc
Oct 19, 2020
04:01PM EDT  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.   GlobeNewswire Inc
Oct 15, 2020
11:52AM EDT  BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $51   Benzinga
10:15AM EDT  Mid-Morning Market Update: Markets Open Lower; Walgreens Profit Beats Views   Benzinga
09:51AM EDT  Benzinga's Top Upgrades, Downgrades For October 15, 2020   Benzinga
08:02AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
06:44AM EDT  HC Wainwright & Co. Upgrades Replimune Group to Buy, Raises Price Target to $54   Benzinga
04:54AM EDT  SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $44   Benzinga
Oct 14, 2020
12:48PM EDT  RepLimune Shares Quiet Following Recent Press Release Highlighting Upcoming Nov. 11, 12 Presentations At Society For Immunotherapy Of Cancer; Includes Links To Abstracts For RP2, RP1   Benzinga
12:29PM EDT  Initial safety and efficacy data from thesingle agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo (nivolumab) in patients with solid tumors   GlobeNewswire Inc
Oct 1, 2020
07:00AM EDT  Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.   GlobeNewswire Inc
Aug 11, 2020
04:53PM EDT  Replimune Group Files For Up To $350M Mixed Shelf Offering   Benzinga
Aug 7, 2020
11:33AM EDT  SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $27   Benzinga
07:23AM EDT  Replimune Group Q1 EPS $(0.44) Down From $(0.30) YoY   Benzinga
07:21AM EDT  Replimune Group Q1 Net Loss $17.5M vs Loss $9.5M In Same Qtr. Last Year   Benzinga
07:00AM EDT  Clinical proof of principle established with RP1 in combination with Opdivo for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory melanoma   GlobeNewswire Inc
Aug 4, 2020
07:00AM EDT  Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.   GlobeNewswire Inc
Jul 22, 2020
07:22AM EDT  Replimune Appoints Andrea Pirzkall As Chief Medical Officer, Effective August 31, 2020   RTTNews
07:00AM EDT  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the strengthening of its executive team with the appointment of Andrea Pirzkall, M.D. as Replimunes Chief Medical Officer effective August 31st, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC